Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Heritage raises $10 million in series A financing
The financing round was led by by Oklahoma City, Oklahoma-based venture capital investors McClendon Venture Company and TLW Venture Company. The proceeds will be utilized to finance North
The financing round was led by by Oklahoma City, Oklahoma-based venture capital investors McClendon Venture Company and TLW Venture Company. The proceeds will be utilized to finance North
The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product
Natus has agreed to acquire all outstanding shares of SonaMed capital stock in a cash transaction. The agreement has received the approval of the boards of directors of
The study involves approximately 600 patients primarily in the US and Canada, with additional sites in Europe. This first efficacy study, a one-year placebo-controlled efficacy study will assess
The companies will work together to enhance the dosing profile for compounds within Amylin’s early R&D pipeline. The goal of the collaboration is to develop multiple products based
Using the complex model system chick chorioallantoic membrane (CAM), researchers observed that topical application or intravenous injection of TM601 inhibited angiogenesis (new blood vessel growth), which was stimulated
In familial hypercholesterolemia (FH) patients exposed to mipomersen for as long as 16 months, the safety profile of the drug continues to be encouraging. Reductions in low-density lipoprotein
According to PharmaTimes, the introduction of mass health insurance, liberalization initiatives and the Middle East governments’s desire to become self-sufficient in pharmaceuticals production may herald a prospective future
Leclerc, a chain of super- and hypermarkets, contended that self-medication products can be sold at a 25% lower price if the pharmacy monopoly on non-reimbursed, non-prescription medicines sales
The funding is expected to help smaller centres conduct high-quality research and achieve critical mass in priority areas, including respiratory and gastrointestinal diseases. The biomedical research units were